Search Results - "Lublin, Fred"

Clinical Course of Multiple Sclerosis by Klineova, Sylvia, Lublin, Fred D

“…The 1996 originally established multiple sclerosis (MS) subtypes, based solely on clinical impression and consensus, were revised in 2013 to review potential…”
Get full text

New multiple sclerosis phenotypic classification by Lublin, Fred D

“…In 1996, the clinical course of multiple sclerosis (MS) was characterized as relapsing-remitting, primary progressive, secondary progressive or progressive…”
Get more information

Worsening MS—A reappraisal of how we characterize the MS disease course by Lublin, Fred D

Get full text

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria by Thompson, Alan J, Banwell, Brenda L, Barkhof, Frederik, Carroll, William M, Coetzee, Timothy, Comi, Giancarlo, Correale, Jorge, Fazekas, Franz, Filippi, Massimo, Freedman, Mark S, Fujihara, Kazuo, Galetta, Steven L, Hartung, Hans Peter, Kappos, Ludwig, Lublin, Fred D, Marrie, Ruth Ann, Miller, Aaron E, Miller, David H, Montalban, Xavier, Mowry, Ellen M, Sorensen, Per Soelberg, Tintoré, Mar, Traboulsee, Anthony L, Trojano, Maria, Uitdehaag, Bernard M J, Vukusic, Sandra, Waubant, Emmanuelle, Weinshenker, Brian G, Reingold, Stephen C, Cohen, Jeffrey A

“…The 2010 McDonald criteria for the diagnosis of multiple sclerosis are widely used in research and clinical practice. Scientific advances in the past 7 years…”
Get full text

How patients with multiple sclerosis acquire disability by Lublin, Fred D, Häring, Dieter A, Ganjgahi, Habib, Ocampo, Alex, Hatami, Farhad, Čuklina, Jelena, Aarden, Piet, Dahlke, Frank, Arnold, Douglas L, Wiendl, Heinz, Chitnis, Tanuja, Nichols, Thomas E, Kieseier, Bernd C, Bermel, Robert A

“…Patients with multiple sclerosis acquire disability either through: (1) Relapse-associated worsening (RAW), or (2) progression independent of relapse activity…”
Get full text

The 2013 clinical course descriptors for multiple sclerosis: A clarification by Lublin, Fred D., Coetzee, Timothy, Cohen, Jeffrey A., Marrie, Ruth A., Thompson, Alan J.

“…The clinical courses of multiple sclerosis were defined in 1996 and refined in 2013 to provide a time-based assessment of the current status of the individual…”
Get full text

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial by Calabresi, Peter A, Dr, Radue, Ernst-Wilhelm, Prof, Goodin, Douglas, MD, Jeffery, Douglas, MD, Rammohan, Kottil W, MD, Reder, Anthony T, MD, Vollmer, Timothy, MD, Agius, Mark A, MD, Kappos, Ludwig, Prof, Stites, Tracy, PhD, Li, Bingbing, PhD, Cappiello, Linda, MD, von Rosenstiel, Philipp, MD, Lublin, Fred D, MD

“…Summary Background Fingolimod has shown reductions in clinical and MRI disease activity in patients with relapsing-remitting multiple sclerosis. We further…”
Get full text

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria by Polman, Chris H., Reingold, Stephen C., Banwell, Brenda, Clanet, Michel, Cohen, Jeffrey A., Filippi, Massimo, Fujihara, Kazuo, Havrdova, Eva, Hutchinson, Michael, Kappos, Ludwig, Lublin, Fred D., Montalban, Xavier, O'Connor, Paul, Sandberg-Wollheim, Magnhild, Thompson, Alan J., Waubant, Emmanuelle, Weinshenker, Brian, Wolinsky, Jerry S.

“…New evidence and consensus has led to further revision of the McDonald Criteria for diagnosis of multiple sclerosis. The use of imaging for demonstration of…”
Get full text

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial by Cree, Bruce A C, Bennett, Jeffrey L, Kim, Ho Jin, Weinshenker, Brian G, Pittock, Sean J, Wingerchuk, Dean M, Fujihara, Kazuo, Paul, Friedemann, Cutter, Gary R, Marignier, Romain, Green, Ari J, Aktas, Orhan, Hartung, Hans-Peter, Lublin, Fred D, Drappa, Jorn, Barron, Gerard, Madani, Soraya, Ratchford, John N, She, Dewei, Cimbora, Daniel, Katz, Eliezer

“…No approved therapies exist for neuromyelitis optica spectrum disorder (NMOSD), a rare, relapsing, autoimmune, inflammatory disease of the CNS that causes…”
Get full text

Deep Learning for Predicting Enhancing Lesions in Multiple Sclerosis from Noncontrast MRI by Narayana, Ponnada A, Coronado, Ivan, Sujit, Sheeba J, Wolinsky, Jerry S, Lublin, Fred D, Gabr, Refaat E

“…Background Enhancing lesions on MRI scans obtained after contrast material administration are commonly thought to represent disease activity in multiple…”
Get full text

MS becomes a treatable disease: 30 years later by Lublin, Fred D, Krieger, Stephen C

“…30 years ago the first disease-modifying therapy for relapsing multiple sclerosis was approved for use in the United States and soon thereafter across the…”
Get full text

Defining the clinical course of multiple sclerosis: The 2013 revisions by Lublin, Fred D, Reingold, Stephen C, Cohen, Jeffrey A, Cutter, Gary R, Sørensen, Per Soelberg, Thompson, Alan J, Wolinsky, Jerry S, Balcer, Laura J, Banwell, Brenda, Barkhof, Frederik, Bebo, Bruce, Calabresi, Peter A, Clanet, Michel, Comi, Giancarlo, Fox, Robert J, Freedman, Mark S, Goodman, Andrew D, Inglese, Matilde, Kappos, Ludwig, Kieseier, Bernd C, Lincoln, John A, Lubetzki, Catherine, Miller, Aaron E, Montalban, Xavier, OʼConnor, Paul W, Petkau, John, Pozzilli, Carlo, Rudick, Richard A, Sormani, Maria Pia, Stüve, Olaf, Waubant, Emmanuelle, Polman, Chris H

“…Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of…”
Get full text

Randomized study combining interferon and glatiramer acetate in multiple sclerosis by Lublin, Fred D., Cofield, Stacey S., Cutter, Gary R., Conwit, Robin, Narayana, Ponnada A., Nelson, Flavia, Salter, Amber R., Gustafson, Tarah, Wolinsky, Jerry S.

“…Objective A double‐blind, randomized, controlled study was undertaken to determine whether combined use of interferon β‐1a (IFN) 30μg intramuscularly weekly…”
Get full text

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study by Havrdova, Eva, MD, Galetta, Steven, MD, Hutchinson, Michael, MD, Stefoski, Dusan, MD, Bates, David, MD, Polman, Chris H, MD, O'Connor, Paul W, MD, Giovannoni, Gavin, PhD, Phillips, J Theodore, MD, Lublin, Fred D, MD, Pace, Amy, ScD, Kim, Richard, MD, Hyde, Robert, PhD

“…Summary Background The efficacy of natalizumab on clinical and radiological measures in the phase III Natalizumab Safety and Efficacy in Relapsing-Remitting…”
Get full text

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial by Lublin, Fred, Prof, Miller, David H, Prof, Freedman, Mark S, Prof, Cree, Bruce A C, Prof, Wolinsky, Jerry S, Prof, Weiner, Howard, Prof, Lubetzki, Catherine, Prof, Hartung, Hans-Peter, Prof, Montalban, Xavier, Prof, Uitdehaag, Bernard M J, Prof, Merschhemke, Martin, MD, Li, Bingbing, PhD, Putzki, Norman, MD, Liu, Fonda C, PharmD, Häring, Dieter A, PhD, Kappos, Ludwig, Prof

“…Summary Background No treatments have been approved for primary progressive multiple sclerosis. Fingolimod, an oral sphingosine 1-phosphate receptor modulator,…”
Get full text

Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum by Koch, Marcus W., Mostert, Jop, Zhang, Yinan, Wolinsky, Jerry S., Lublin, Fred D., Strijbis, Eva, Cutter, Gary

“…To investigate the association of age and the presence of contrast-enhancing lesions (CELs) on cranial MRI scans in different disease courses of multiple…”
Get full text

Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis by Koch, Marcus W, Mostert, Jop P, Wolinsky, Jerry S, Lublin, Fred D, Uitdehaag, Bernard, Cutter, Gary R

“…Clinical trials in relapsing-remitting multiple sclerosis (RRMS) usually use the Expanded Disability Status Scale (EDSS) as their primary disability outcome…”
Get full text

Brain and lesion segmentation in multiple sclerosis using fully convolutional neural networks: A large-scale study by Gabr, Refaat E, Coronado, Ivan, Robinson, Melvin, Sujit, Sheeba J, Datta, Sushmita, Sun, Xiaojun, Allen, William J, Lublin, Fred D, Wolinsky, Jerry S, Narayana, Ponnada A

“…Objective: To investigate the performance of deep learning (DL) based on fully convolutional neural network (FCNN) in segmenting brain tissues in a large…”
Get full text

Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial by Cree, Bruce A C, Cutter, Gary, Wolinsky, Jerry S, Freedman, Mark S, Comi, Giancarlo, Giovannoni, Gavin, Hartung, Hans-Peter, Arnold, Douglas, Kuhle, Jens, Munschauer, Frederick E, Sedel, Frédéric, Lublin, Fred D, Reingold, Stephen, Duquette, Pierre, Derfuss, Tobias, Sormani, Maria Pia, Lisak, Robert P., Graves, Jennifer, Krieger, Stephen, Zabad, Rana K., Newsome, Scott, MacDonell, Richard, Marriott, Mark, De Klippel, Nina, Willekens, Barbara, Devonshire, Virginia, Freedman, Mark, Girard, J Marc, Giacomini, Paul, McKelvey, Roger, Witkowski, Ludivine, Ampapa, Radek, Preiningerova, Jana Lizrova, Meluzinova, Eva, Talab, Radomir, Vachova, Marta, Aktas, Orhan, Buttmann, Mathias, Birte, Elias-Hamp, Kuempfel, Tania, Friedemann, Paul, Rau, Daniela, Reifschneider, Gerd, Sokolowski, Piotr, Tumani, Hayrettin, Pozzilli, Carlo, Klosek, Agata, Koscielniak, Jozef, Waldemar, Fryze, Zajda, Malgorzata, Gonzalez, Rafael Arroyo, Ayuso, Guillermo Izquierdo, Sanchez, Victoria Fernandez, Guevara, Celia Oreja, Rodriguez, Jose Enrique Martinez, Montalban, Xavier, Ramio-Torrenta, Lluis, Brundin, Lou, Lycke, Jan, Guadagno, Joe, Mahad, Don, Pace, Adrian, Schmierer, Klaus, Toosy, Ahmed, Webb, Stewart, Agius, Mark, Apperson, Michelle, Bagert, Bridget, Bandari, Daniel, Bernitsas, Evanthia, Calkwood, Jonathan, Carter, Jonathan, Conway, Devon, Cooper, Joanna, Corboy, John, Cree, Bruce, Freedman, Mitchel, Ford, Corey, Fox, Edward, Goldman, Myla, Kita, Mariko, Lynch, Sharon, Miller, Aaron, Moses, Harold, Naismith, Robert, Picone, Mary Ann, Perminder, Bhatia, Rae-Grant, Alexander, Rammohan, Kottil, Reder, Anthony, Riley, Claire, Robertson, Derrick, Rowe, Vernon, Saidha, Shiv, Samkoff, Lawrence, Severson, Christopher, Smoot, Kyle, Stoll, Sharon, Weinstock-Guttman, Bianca, Yathiraj, Sanjay

“…There is an unmet need to develop therapeutic interventions directed at the neurodegeneration that underlies progression in multiple sclerosis. High-dose,…”
Get full text

Deep‐Learning‐Based Neural Tissue Segmentation of MRI in Multiple Sclerosis: Effect of Training Set Size by Narayana, Ponnada A., Coronado, Ivan, Sujit, Sheeba J., Wolinsky, Jerry S., Lublin, Fred D., Gabr, Refaat E.

“…Background The dependence of deep‐learning (DL)‐based segmentation accuracy of brain MRI on the training size is not known. Purpose To determine the required…”
Get full text